UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
British journal of pharmacology, ISSN 0007-1188, 06/2008, Volume 154, Issue 3, pp. 502 - 521
clinical | performance | receptor | anabolic steroids | health | SARMs | designer | mechanism | sport | Designer | Sport | Health | Receptor | Anabolic steroids | Clinical | Performance | Mechanism | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Anabolic Agents - pharmacology | Animals | Receptors, Androgen - drug effects | Humans | Receptors, Androgen - metabolism | Anabolic Agents - adverse effects | Female | Male | Steroids - pharmacology | Doping in Sports | Athletic Performance - physiology | Steroids - adverse effects | Index Medicus | Themed Reviews
Journal Article
2.
Full Text
Identification of black market products and potential doping agents in Germany 2010–2013
European journal of clinical pharmacology, ISSN 0031-6970, 11/2014, Volume 70, Issue 11, pp. 1303 - 1311
Sport | Biomedicine | Thymosin β4 | Doping | Black market | Pharmacology/Toxicology | Mass spectrometry | LGD-4033 | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Medical sciences | Drug intoxications. Doping | Pharmacology. Drug treatments | Central Nervous System Stimulants - analysis | Estrogen Receptor Modulators - analysis | Hormones - analysis | Steroids - analysis | Doping in Sports | Germany | Street Drugs - analysis | Drugs and athletes | Testosterone | Somatotropin | Estrogen | Thymosin | Diuretics | Anabolic steroids | Liquid chromatography | Pharmacology | Black markets | Hormones | Drugs & sports | Risk factors | Index Medicus
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 01/2013, Volume 56, Issue 1, pp. 109 - 122
Gene Expression - drug effects | Humans | Coumarins - chemistry | Crystallography, X-Ray | Quinolones - pharmacology | Structure-Activity Relationship | Anabolic Agents - chemistry | Bone and Bones - drug effects | Anabolic Agents - pharmacology | Quinolones - chemistry | Quinolones - chemical synthesis | Female | Cell Differentiation | Osteoblasts - cytology | Osteoporosis, Postmenopausal - etiology | Biomarkers - metabolism | Bone Resorption - physiopathology | Bone and Bones - physiology | Dihydropyridines - chemistry | Calcification, Physiologic - drug effects | Ovariectomy | Administration, Oral | Osteoblasts - drug effects | Osteogenesis - drug effects | Bone Resorption - drug therapy | Osteoporosis, Postmenopausal - drug therapy | Coumarins - pharmacology | Bone Density - drug effects | Dihydropyridines - chemical synthesis | Animals | Coumarins - chemical synthesis | Anabolic Agents - chemical synthesis | Dihydropyridines - pharmacology | Osteoporosis, Postmenopausal - physiopathology | Mice | Osteoblasts - metabolism | Index Medicus
Journal Article
Osteoporosis international, ISSN 0937-941X, 3/2016, Volume 27, Issue 3, pp. 861 - 871
Osteoporosis | Medicine & Public Health | Orthopedics | Rheumatology | Medication | Fracture healing | Pharmacology | Endocrinology | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Calcitonin - pharmacology | Thiophenes - therapeutic use | Anabolic Agents - therapeutic use | Humans | Bone Density Conservation Agents - therapeutic use | Thiophenes - pharmacology | Calcitonin - therapeutic use | Osteoporosis - drug therapy | Evidence-Based Medicine | Bone Density Conservation Agents - pharmacology | Denosumab - therapeutic use | Anabolic Agents - pharmacology | Animals | Fracture Healing - drug effects | Diphosphonates - therapeutic use | Denosumab - pharmacology | Osteoporotic Fractures - physiopathology | Diphosphonates - pharmacology | Disease Models, Animal | Analysis | Estrogen | Phosphonates | Fracture fixation | Drug therapy | Health aspects | Medicine | Fractures | Index Medicus
Journal Article
Clinical orthopaedics and related research, ISSN 0009-921X, 8/2011, Volume 469, Issue 8, pp. 2215 - 2224
Surgical Orthopedics | Medicine & Public Health | Sports Medicine | Surgery | Orthopedics | Conservative Orthopedics | Medicine/Public Health, general | Life Sciences & Biomedicine | Science & Technology | Parathyroid Hormone - physiology | Anabolic Agents - therapeutic use | Bone and Bones - physiology | Bone Morphogenetic Proteins - physiology | Teriparatide - administration & dosage | Humans | Peptide Fragments - administration & dosage | Prostaglandins - agonists | Thiophenes - pharmacology | Osteoporosis - drug therapy | Teriparatide - analogs & derivatives | Bone Remodeling - physiology | Bone Density Conservation Agents - administration & dosage | Bone Remodeling - drug effects | Focal Adhesion Kinase 2 - physiology | Bone Density Conservation Agents - pharmacology | Bone and Bones - drug effects | Anabolic Agents - pharmacology | Animals | Fracture Healing - drug effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Genetic Markers - physiology | Insulin-Like Growth Factor I - therapeutic use | Organometallic Compounds - pharmacology | Tyrosine | Online health care information services | Prostaglandins | Parathyroid hormone | Analysis | Bones | Hormones | Mechanical engineering | Density | Statins | Quality management | Animal models | Clinical trials | SOST protein | Bioavailability | Bone diseases | Strontium | proline-rich tyrosine kinase 2 | Fractures | statins | Bone mineral density | Bone composition | Injuries | Index Medicus | Abridged Index Medicus | Bone Quality | From Bench to Bedside | Symposium
Journal Article
European journal of pharmacology, ISSN 0014-2999, 03/2015, Volume 750, pp. 141 - 150
NF-κB | MAPK | Chronic inflammation | Natural products | Osteoarthritis | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Gene Expression Regulation, Enzymologic - drug effects | Interleukin-1beta - pharmacology | Humans | Middle Aged | Extracellular Matrix - metabolism | NF-kappa B - metabolism | Terpenes - pharmacology | Young Adult | Chondrocytes - drug effects | Monoterpenes - pharmacology | Anabolic Agents - pharmacology | Collagen Type I - genetics | Adult | Osteoarthritis - pathology | Chondrocytes - metabolism | Matrix Metalloproteinase 1 - genetics | Interleukin-1beta - antagonists & inhibitors | Tissue Inhibitor of Metalloproteinase-3 - genetics | Nitric Oxide - biosynthesis | Anti-Inflammatory Agents - pharmacology | Extracellular Matrix - drug effects | Matrix Metalloproteinase 13 - genetics | Enzyme Activation - drug effects | Aggrecans - genetics | Collagen Type II - genetics | Chondrocytes - enzymology | Tissue Inhibitor of Metalloproteinase-1 - genetics | Nitric Oxide Synthase Type II - genetics | Cyclohexenes - pharmacology | Aged | Sesquiterpenes - pharmacology | Alkenes - pharmacology | Mitogen-Activated Protein Kinases - metabolism | Neurosciences | Anti-inflammatory drugs | Collagen | Analysis | Nitric oxide | Pharmacy | Drugstores | Cells | Index Medicus
Journal Article
Journal of ethnopharmacology, ISSN 0378-8741, 09/2014, Volume 155, Issue 3, pp. 1401 - 1416
Osteoporosis | Salvia miltiorrhiza | Anti-resorptive activity | Pro-anabolic activity | Danshen | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Integrative & Complementary Medicine | Plant Sciences | Science & Technology | Anabolic Agents - therapeutic use | Salvia miltiorrhiza - chemistry | Anabolic Agents - pharmacology | Animals | Phytochemicals - analysis | Humans | Bone Density Conservation Agents - therapeutic use |